has been a loss of about Rs. 120 crores by increase in the re-quoted price; about Rs. 50 crores because of variation in the exchange rate; and about Rs. 400 crores in terms of loss of revenue; and

(c) if so, what steps have been taken by Government to avoid these losses ?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRI KALPNATH RAI) : (a) to (c) All the parties (including M/s. Alsthom, France) who had purchased the bid documents when the tenders were first floated, were intimated to re-bid for the Kawas project. No decision has been taken so far in respect of award of the contract.

Prices of Combiflame

3. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) what is the price of combiflame at which it is being marketed at present and since when this is being marked at this price;

(b) whether it is a fact that his Ministry fixed the price of this product under DPCO, 1979;

(c) if so, when and what price was fixed;

(d) whether it is also a fact that the price was re-fixed under DPCO, 1987;

(e) if so, when and what price was fixed;

(f) whether it is a fact that the company neither implemented the price fixed under DPCO, 1979 nor under DPCO, 1987 and overcharged the poor people;

(g) whether it is a fact that his Ministry received complaints in this regard; and

(h) if so, what are the details thereof and action taken by Government thereon?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) as per Indian Pharmaceutical Guide, 1988, price charged for 10's Strip of Combiflam Tablets by M/s. Roussel Pharmaceuticals (India) Ltd., was Rs. 12.19.

(b) and (c) A price of Rs. 7.68 was fixed under DPCO, 1979 for this formulation pack on 5-11-1986.

(d) and (e) A revised price of Rs. 4.90 was *sou-moto* fixed by the Govt. for this pack as Category-I formulation under DPCO, 1987 on 2-12-1988.

(f) to (h) In reply to a show cause notice issued by the Govt., the Manufacturer company M/s. Carews Pharmaceutical Ltd. has claimed that being an SSI unit, they are exempted from price control on their Category-II formulations. With the shifting of Paracetamol from Schedule I of DPCO, 1987 to Schedule II, w.e.f. 18-1-1989, Combiflam now falls under Category-II. The matter is being further examined.

Prices of Troxyvon and Butaproxyvon

4. SHRI M. KADHARSHA : Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the prices of Proxyvon and Butaproxyvon are still being overcharged by the drug company;

(b) when and what were the prices of these products fixed for the first time under DPCO 1979 and what were the prices fixed under DPCO 1987;